Response | Comparison | MD±SE | 95% CI† | P value |
TNF-α | CAD+OA vs Ctrl | 3.228±1.425 | 1.350 to 7.714 | 0.005* |
CAD+OA vs CAD | 2.504±1.266 | 1.402 to 4.468 | 0.001* | |
CAD vs Ctrl | 1.289±1.363 | 0.600 to 2.768 | >0.999 | |
IFN-γ | CAD+OA vs Ctrl | 1.514±1.212 | 0.944 to 2.430 | 0.104 |
CAD+OA vs CAD | 1.254±1.126 | 0.936 to 1.680 | 0.185 | |
CAD vs Ctrl | 1.207±1.196 | 0.777 to 1.876 | 0.888 | |
MDA | CAD+OA vs Ctrl | 1.865±1.189 | 1.219 to 2.852 | 0.002* |
CAD+OA vs CAD | 1.182±1.120 | 0.894 to 1.565 | 0.437 | |
CAD vs Ctrl | 1.576±1.162 | 1.091 to 2.277 | 0.010* | |
NOx | CAD+OA vs Ctrl | 1.070±1.038 | 0.977 to 1.172 | 0.207 |
CAD+OA vs CAD | 0.997±1.025 | 0.938 to 1.059 | >0.999 | |
CAD vs Ctrl | 1.075±1.034 | 0.991 to 1.165 | 0.100 |
*Significant difference was considered at p<0.05.
†Back-transformed coefficients using the exponential function.
ANOVA, analysis of variance; CAD, coronary artery disease; CAD+OA, coronary artery disease and opium addiction; Ctrl, control; IFN-γ, interferon gamma; MD, mean difference; MDA, malondialdehyde; NOx, nitric oxide metabolites; TNF-α, tumor necrosis factor alpha.